Diabetes

RNA-based therapy for Diabetes: LncRNA BRM increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 4/January/2019, 12.58 pm
RNA-based therapy for Diabetes: LncRNA BRM increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 4/January/2019, 12.58 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, the University of Alabama at Birmingham, Birmingham, AL shows…

read more

RNA-based therapy for Diabetes: LncRNA ADNCR increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 4/January/2019, 12.29 pm
RNA-based therapy for Diabetes: LncRNA ADNCR increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 4/January/2019, 12.29 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, the University of Alabama at Birmingham, Birmingham, AL shows…

read more

RNA-based therapy for Diabetes: LncRNA TUG1 increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 4/January/2019, 9.31 am
RNA-based therapy for Diabetes: LncRNA TUG1 increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 4/January/2019, 9.31 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, the University of Alabama at Birmingham, Birmingham, AL shows…

read more

Molecular therapy for diabetes (TIDM): Ramipril (trade names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others),), a drug used in the treatment of hypertension and cardiac dysfunction, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 28/December/2018, 11.25 pm
Molecular therapy for diabetes (TIDM): Ramipril (trade names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others),), a drug used in the treatment of hypertension and cardiac dysfunction, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 28/December/2018, 11.25 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Molecular therapy for Diabetes Mellitus: Venlafaxine (brand name: Effexor), an anti-depressant, increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 28/December/2018, 11.06 pm
Molecular therapy for Diabetes Mellitus: Venlafaxine (brand name: Effexor), an anti-depressant, increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 28/December/2018, 11.06 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study…

read more

Erythropoietin-based therapy for glucose homeostasis and TIIDM: Erythropoietin/hematopoietin increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM, via down regulation of its target gene, 28/December/2018, 10.58 pm
Erythropoietin-based therapy for glucose homeostasis and TIIDM: Erythropoietin/hematopoietin increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM, via down regulation of its target gene, 28/December/2018, 10.58 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that…

read more
Start Typing